JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase

20260 citationsJournal Articlehybrid Open Access

Authors

Marilou Duboëlle · Centre Occitanie-Montpellier

Adriano Lercara · Centre Hospitalier Universitaire de Montpellier

Yves‐Marie Pers · Inserm

Céline Michel · Centre de Réadaptation Cardiaque Les Grands Prés

Marion Lepelley · Centre Hospitalier Universitaire de Grenoble

Marie‐Blanche Valnet‐Rabier · Centre Hospitalier Universitaire de Besançon

Jean‐Luc Faillie

Abstract

Our data support the positive association between MI and JAKi, potentially mediated through hippocampal JAK/STAT pathway inhibition, impairing cholinergic neurotransmission and synaptic plasticity. While further investigations are warranted to confirm or refute this pharmacovigilance signal, clinicians should remain vigilant given this potentially serious adverse effect.

Topics & Keywords

Pharmacovigilance and Adverse Drug Reactions Psoriasis: Treatment and Pathogenesis Drug-Induced Adverse Reactions

Publication Details

Published in: Fundamental and Clinical Pharmacology

Volume 40, Issue 1, pp. e70072-e70072

DOI: 10.1111/fcp.70072

Field-Weighted Citation Impact: 0.00

Command Palette

JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase

Authors

Abstract

Topics & Keywords

Publication Details